Children's cough syrup recalled due to possibly deadly food poisoning risk: ‘Stop using it immediately'
Parents: You might want to check your medicine cabinet.
A New York-based pharmaceutical company is voluntarily recalling several batches of a popular children's cough syrup over fears they may be contaminated with harmful bacteria.
The Food and Drug Administration is urging consumers to 'stop using it immediately' if they have any of the affected lots of Little Remedies® Honey Cough Syrup, according to an alert issued by the agency on Wednesday.
Advertisement
3 The recalled product may contain Bacillus cereus
Little Remedies
The affected bottles were sold both in stores and online between Dec. 14, 2022, and June 4, 2025.
The syrup comes in a 4-fluid-ounce amber bottle, packaged in an outer carton. Lot codes, which identify the recalled products, can be found on the bottle label and the bottom of the box.
Advertisement
The following five batches are affected:
3
FDA
No other Little Remedies products are part of the recall.
Syrup affected by the recall may be tainted with Bacillus cereus, a bacteria that can lead to two types of food-borne illnesses, according to the FDA.
Advertisement
One causes nausea, vomiting, and stomach cramps within six hours of exposure. The other triggers diarrhea and cramping, typically 8 to 16 hours after use.
3 The product is intended for children ages 1 year and older.
redpepper82 – stock.adobe.com
'While healthy individuals may suffer only short-term illness, exposure to high levels of B. cereus can be fatal,' the agency said in an alert.
So far, no illnesses have been reported. The FDA recommends that anyone experiencing symptoms seek medical attention and report any adverse reactions through their website.
Advertisement
Manufacturer, Medtech, is offering full refunds for the recalled products.
Customers can contact the company directly by email at medicalaffairs@prestigebrands.com, through its website or by phone at (800) 754-8853 from 8:30 a.m. – 5:30 p.m. Monday through Friday.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Upturn
an hour ago
- Business Upturn
HealthRX Expands Telehealth Website Experience to Include GLP-1 Weight Loss Solutions, Prescription Access, and 24/7 Wellness Support
BROOKLYN, June 19, 2025 (GLOBE NEWSWIRE) — HealthRX, a digital health platform serving adults across the United States, has announced an expanded online experience designed to support weight management and long-term wellness through a suite of integrated offerings. These include Health RX Telehealth™, Health RX Prescription Access™, and Health RX Wellness Support™, all accessible through its newly enhanced website at The update provides streamlined access to GLP-1 medications such as Ozempic®, Zepbound®, and compounded alternatives—subject to eligibility criteria and clinical discretion. The HealthRX platform is built to accommodate adults who are seeking a secure, doctor-supervised weight management option that minimizes barriers to care and supports routine-friendly wellness. A Digital Health Platform Designed for Results HealthRX offers a simplified path for adults to explore medically appropriate weight loss options from the comfort of home. Through the HealthRX intake process, users can connect with U.S.-licensed physicians to determine clinical eligibility for GLP-1 medications. The program emphasizes convenience and flexibility, removing the need for in-person consultations or insurance requirements. The platform's design integrates: Health RX Telehealth™ – Secure access to virtual consultations with board-certified physicians. – Secure access to virtual consultations with board-certified physicians. Health RX Prescription Access™ – Direct, encrypted coordination with pharmacies for prescription fulfillment and renewals. – Direct, encrypted coordination with pharmacies for prescription fulfillment and renewals. Health RX Wellness Support™ – A collection of tools including coaching support, educational resources, medication reminders, and outcome tracking. Each service is built to align with common adult health goals—particularly those related to sustained weight management. Full details are available on the official HealthRX website at Highlight on GLP-1 Medication Access: Ozempic®, Zepbound®, and Tirzepatide Options GLP-1 medications have emerged as a physician-supervised option for individuals managing obesity or weight-related conditions. HealthRX facilitates access to FDA-approved GLP-1 treatments such as Ozempic®, Zepbound®, and Tirzepatide®, as well as compounded GLP-1 or GLP-1/GIP medications based on clinical suitability. These medications work by targeting appetite regulation and glucose control pathways and are prescribed in accordance with FDA labeling or compound-specific clinical judgment. The HealthRX platform outlines potential usage scenarios, average pricing tiers, and expected timelines for prescription delivery—all while emphasizing that outcomes vary by individual. For medication access information, visit HealthRX also confirms that compounded medications offered through the platform are prepared in U.S.-based facilities in accordance with USP <795> and <797> standards. The company notes that compounded drug products are not FDA-approved, and eligibility is determined during the virtual consultation process with a licensed provider. Three-Step Process Designed for Accessibility Visitors to the website are guided through a simple three-step intake process: Take the Assessment – Users begin by completing a short clinical questionnaire to determine preliminary eligibility. Meet a Board-Certified Physician – Within 24 hours, eligible users are connected to a licensed medical provider for an evaluation. Receive Medication – Upon approval, GLP-1 prescriptions are delivered securely to the patient's door with ongoing support available. This process is designed to make adult wellness and weight loss support accessible without long wait times, insurance hassles, or frequent office visits. A full description is provided at Pricing and Support Structure As listed on the platform: Ozempic® (Brand GLP-1) – $1,299/month (In Stock) – $1,299/month (In Stock) Tirzepatide® (GLP-1 + GIP) – $1,299/month (Limited Stock) – $1,299/month (Limited Stock) GLP-1 Injections (Compounded) – $189/month (Low Stock) – $189/month (Low Stock) GLP-1 Oral Tablets (Compounded) – $239/month (Low Stock) – $239/month (Low Stock) GLP-1 + GIP Injection (Compounded) – $349/month (In Stock) Pricing reflects bundled services that include medical evaluation, platform access, prescription coordination, and support. Details and plan tiers are explained at Transparent Clinical Oversight All HealthRX-affiliated physicians are U.S.-licensed and board-certified in relevant specialties such as internal medicine, emergency care, osteopathic medicine, and family medicine. Provider credentials and bios are available through the HealthRX platform. HealthRX confirms that all consultations, messaging, and record keeping are conducted through encrypted channels in compliance with HIPAA regulations. Privacy and user consent policies are explained at Health RX Wellness Support™ Adds a Preventive Layer Health RX Wellness Support™ complements prescription and telehealth services by offering educational and lifestyle tools, including: Digital health journals and medication tracking Reminder alerts for check-ins and prescription refills Curated content on nutrition, movement, and self-care Access to secure provider messaging These tools aim to reinforce adherence and increase long-term success for adults pursuing medically guided weight loss. More about the support program can be found at Verified Customer Experiences HealthRX highlights verified user reviews collected by third-party platforms: 'Signing up took less than five minutes, and the process was clear.' 'The support staff answered every question. I already feel healthier.' 'After starting the treatment, I received my delivery within 48 hours.' Individual experiences are unique, and HealthRX maintains a strict no-guarantee policy regarding outcomes. Additional testimonials and review information are linked from Platform Policies and Consumer Disclosures HealthRX outlines its key platform policies, including: No charge if a user does not qualify Cancellation is available anytime without penalties Refunds are processed within 24–48 hours if eligibility is not met Insurance is not required but may be used independently for reimbursement These policies are detailed in the platform's Terms of Service and FAQ sections at About HealthRX HealthRX is a U.S.-based virtual healthcare platform offering GLP-1-based weight management, online prescription access, and ongoing support through secure telehealth services. The platform includes Health RX Telehealth™, Health RX Prescription Access™, and Health RX Wellness Support™, designed to provide adults with personalized, remote wellness strategies. HealthRX is not a healthcare provider itself, but coordinates licensed services through verified clinical partners. More about the HealthRX platform can be found at Product and Contact Information Products and Services: Health RX Telehealth™ Health RX Prescription Access™ Health RX Wellness Support™ GLP-1 Medications: Ozempic®, Zepbound®, Tirzepatide®, Compounded Options Website: Contact Email: [email protected] Phone: +1 (208) 494-2534 Disclaimer This release is for informational purposes only and does not constitute medical advice, diagnosis, or treatment. Individual results may vary. Consumers should consult a licensed medical provider for personalized recommendations. HealthRX does not guarantee eligibility, outcomes, or medication access. GLP-1 medications may cause serious side effects, including possible thyroid tumors. Do not use if you or a family member have a history of medullary thyroid carcinoma (MTC) or MEN 2. Compounded drugs are not FDA-approved, and their safety and effectiveness have not been evaluated by the FDA. HealthRX does not manufacture, prescribe, or dispense medication directly. All services are provided through licensed third parties. Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. Business Upturn takes no editorial responsibility for the same. Ahmedabad Plane Crash
Medscape
4 hours ago
- Medscape
Injectable HIV Prevention Drug Gets FDA Nod
Individuals at risk for sexually acquired HIV have a new injectable option for preexposure prophylaxis (PrEP) with the US Food and Drug Administration's (FDA's) approval of lenacapavir, according to a press release from manufacturer, Gilead. Lenacapavir, marketed as Yeztugo, is the first twice-yearly injectable to be indicated for PrEP for adults and adolescents weighing at least 35 kg (approximately 77 lb). Lenacapavir is administered via an injection into the subcutaneous layer of fat in the abdomen. The resulting 'drug depot' may feel like a bump or nodule but resolves or shrinks before the next injection, according to the company. The approval was based on data from a pair of studies, PURPOSE 1 and PURPOSE 2. In the PURPOSE 1 study, published in The New England Journal of Medicine, lenacapavir was 100% effective in preventing HIV infection compared to background HIV incidence in cisgender women and significantly more effective than daily oral combination therapy of emtricitabine and tenofovir disoproxil fumarate (Truvada). Notably, the study included pregnant women and adolescents, and the drug was generally well tolerated. In the PURPOSE 2 study, also published in NEJM, lenacapavir was similarly effective for HIV infection prevention in a population of cisgender men and gender-diverse persons, with only two infections in the more than 2000 individuals randomized to lenacapavir. Overall, the injection was well tolerated but is contraindicated for individuals who test positive for HIV; a negative test is required before each injection, according to the company. The specifics of cost and insurance coverage for lenacapavir remain to be seen, but Gilead's Advancing Access medication assistance program will provide the drug at no cost to eligible patients, according to the press release. Lenacapavir was granted Breakthrough Therapy Designation by the FDA in October 2024 and was approved under the FDA's Priority Review process. Gilead has submitted a marketing authorization application with the European Medicines Agency and filed for regulatory approval in multiple countries worldwide including Australia, Brazil, Canada, and South Africa. The PURPOSE 1 and 2 studies were funded by Gilead.
Yahoo
5 hours ago
- Yahoo
What to know about COVID variant NB.1.8.1 causing 'razor blade throat'
A newer COVID-19 variant may be causing a severe sore throat in some people who contract the infection. The variant, known as NB.1.8.1, has been nicknamed by some as "razor blade throat" due to the painful symptom. MORE: Why are more than 300 people in the US still dying from COVID every week? Data from the open global genome sequencing database GISAID shows the new variant has been detected in several states, including New York, Illinois, Texas and California. Public health experts told ABC News there is no cause for serious concern yet because the virus does not appear to be more severe than previous variants and there are steps that can be taken to protect yourself. NB.1.8.1 derives from the recombinant variant XVD.1.5.1, which is a descendant of the omicron variant. The first sample of NB.1.8.1 was collected on Jan. 22, according to the World Health Organization (WHO). It was first detected in China and other parts of Asia before spreading to Europe. It was designated as a "variant under monitoring" by the WHO, meaning it may require prioritized attention and monitoring but is not as serious as a "variant of interest" or a "variant of concern." As of the week ending June 7, NB.1.8.1 is the second most dominant variant in the U.S., accounting for an estimated 37% of cases, according to the Centers for Disease Control and Prevention (CDC). The virus appears to be more transmissible because there appear to be changes to the spike protein, which is what the virus uses to attach to and infect cells, said Dr. Peter Chin-Hong, a professor of medicine and infectious disease specialist at the University of California, San Francisco. It also seems to attach more easily to ACE2 receptors, which are proteins found on the surface of cells and how the virus that causes COVID enters cells, he told ABC News. NB.1.8.1 doesn't yet appear to be causing increases in cases or in hospitalizations with rates remaining "stable" so far, according to Chin-Hong. The variant has also been called "Nimbus," which appears to have been coined on X by T. Ryan Gregory, a Canadian professor of evolutionary biology. "Nimbus is a catchy, quick name, and it also includes an 'N' and a 'B' from the lineage, which is NB.1.8.1. So it's easier for people to be able to say these monikers for COVID, rather than remember the actual lineage," said Dr. Alok Potel, a pediatrician at Stanford Children's Health and an ABC News contributor. "But I think it's important also because it keeps people paying attention to new COVID variants that can be different in terms of infectivity and in terms of spread," he added. MORE: What we still don't know about COVID 5 years after the WHO declared a pandemic Experts said they are not sure if the painful sore throat is just a symptom that people are talking about or a distinctive symptom of this variant. It's also unclear if the "razor blade throat" is more common in those who are more up to date on vaccination compared to those who are not up to date. "I think it's certainly amongst the spectrum of symptoms that you can get, and we know that sore throat is reported by about 70% of patients now with COVID, so it's not unusual, and like with everything in medicine, there's always a spectrum," Chin-Hong said. There is currently no evidence that NB.1.8.1. causes more severe disease or is more likely to cause hospitalization, according to Dr. William Schaffner, a professor of preventive medicine at Vanderbilt University Medical Center in Nashville, MORE: 5 years ago, the WHO declared COVID a pandemic. Here's a look at the disease by the numbers "But of course, there are people in high-risk groups that are still at risk of being hospitalized should they become infected," he told ABC News. There are no other symptoms outlined that are specific to NB.1.8.1 by the CDC. Symptoms listed by the health agency still include sore throat, cough, fever, chills, shortness of breath, difficulty breathing, congestion, runny nose, loss of taste or smell, fatigue, muscle aches, body aches, headache, nausea, vomiting or diarrhea. The experts recommend that high-risk Americans receive a vaccine twice a year as recommended by the CDC. The CDC also currently recommends most adults aged 18 and older receive an updated 2024-2025 vaccine and that parents of children between ages 6 months to 17 years discuss the benefits of vaccination with a health care provider. COVID-19 also tends to spike in the late summer and early fall, so people should consider opening windows to increase ventilation, wearing a mask in certain situations and avoiding crowded areas, Schaffner said. "Time to stream a movie, as I like to say, rather than going to the movies," he added. Patel said it's important to practice good hygiene such as proper hand-washing and covering your mouth when coughing or sneezing. He also recommended that people test if they are symptomatic and said over-the-counter rapid at-home tests work. "Getting infected with COVID and other infectious diseases is not necessarily life or death, but it can still be very debilitating." Patel said. "It can cause people to miss work, to spread the virus, to get people who are higher risk sick and there's still an untold amount of people who have long COVID." He added, "So, we don't want to look at COVID as just another common cold, because there's still so much we're learning about it, and there's still so many possibilities with this virus continuing to mutate, if we let it."
